336 related articles for article (PubMed ID: 28960945)
21. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
22. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
24. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
25. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I; Martin SA; Barbarino M; Melani A; Silvestri R; Bottaro M; Paolicchi E; Corrado A; Cipollini M; Melaiu O; Giordano A; Luzzi L; Gemignani F; Landi S
Invest New Drugs; 2021 Jun; 39(3):644-657. PubMed ID: 33300108
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Van TT; Hanibuchi M; Kakiuchi S; Sato S; Kuramoto T; Goto H; Mitsuhashi A; Nishioka Y; Akiyama S; Sone S
Cancer Chemother Pharmacol; 2011 Aug; 68(2):497-504. PubMed ID: 21079960
[TBL] [Abstract][Full Text] [Related]
27. The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1.
Lee KA; Lee YJ; Ban JO; Lee YJ; Lee SH; Cho MK; Nam HS; Hong JT; Shim JH
Int J Mol Med; 2012 Jul; 30(1):21-7. PubMed ID: 22552784
[TBL] [Abstract][Full Text] [Related]
28. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway.
Yang ZP; Zhao Y; Huang F; Chen J; Yao YH; Li J; Wu XN
World J Gastroenterol; 2015 Sep; 21(36):10385-99. PubMed ID: 26420965
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms.
Bjune K; Wierød L; Naderi S
PLoS One; 2019; 14(6):e0218537. PubMed ID: 31216345
[TBL] [Abstract][Full Text] [Related]
30. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Jänne PA; Taffaro ML; Salgia R; Johnson BE
Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
[TBL] [Abstract][Full Text] [Related]
32. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
[TBL] [Abstract][Full Text] [Related]
33. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
34. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
35. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.
Indovina P; Giorgi F; Rizzo V; Khadang B; Schenone S; Di Marzo D; Forte IM; Tomei V; Mattioli E; D'Urso V; Grilli B; Botta M; Giordano A; Pentimalli F
Oncogene; 2012 Feb; 31(7):929-38. PubMed ID: 21785466
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Fischer B; Frei C; Moura U; Stahel R; Felley-Bosco E
Lung Cancer; 2012 Oct; 78(1):23-9. PubMed ID: 22857894
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells.
Chae JI; Jeon YJ; Shim JH
Oncol Rep; 2013 Jun; 29(6):2318-24. PubMed ID: 23525508
[TBL] [Abstract][Full Text] [Related]
38. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
Laszlo V; Valko Z; Ozsvar J; Kovacs I; Garay T; Hoda MA; Klikovits T; Stockhammer P; Aigner C; Gröger M; Klepetko W; Berger W; Grusch M; Tovari J; Waizenegger IC; Dome B; Hegedus B
J Mol Med (Berl); 2019 Feb; 97(2):231-242. PubMed ID: 30539198
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
